2023 ESC Guidelines for the management of acute coronary syndromes Page 1 2023 ESC
Guidelines for the management of acute coronary syndromes Developed by the task force on …

Importance Acute coronary syndromes (ACS) are characterized by a sudden reduction in
blood supply to the heart and include ST-segment elevation myocardial infarction (STEMI) …

Antiplatelet therapy is key to reducing local thrombotic complications and systemic
ischaemic events among patients undergoing percutaneous coronary interventions (PCI) …

Health professionals are encouraged to take the ESC Guidelines fully into account when
exercising their clinical judgment, as well as in the determination and the implementation of …

Background Patients with peripheral artery disease who have undergone lower-extremity
revascularization are at high risk for major adverse limb and cardiovascular events. The …

Surveys and registries are needed to verify that real-life daily practice is in kee** with what
is recommended in the guidelines, thus completing the loop between clinical research …

Guidelines, Aspirin, Clopidogrel, Ticagrelor, Prasugrel, Dual antiplatelet therapy, Acute
coronary syndromes, Coronary artery bypass grafting, Coronary artery disease, Drug-eluting …

Background The relative merits of ticagrelor as compared with prasugrel in patients with
acute coronary syndromes for whom invasive evaluation is planned are uncertain. Methods …

Aims Guidelines recommend the use of potent P2Y12 inhibitors over clopidogrel for the
reduction of ischaemic events in patients with acute coronary syndrome (ACS). However …

Background Current guidelines recommend potent platelet inhibition with ticagrelor or
prasugrel in patients after an acute coronary syndrome. However, data about optimal …